ArticlePloS one2011

A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia.

Carmen D Schweighofer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.